New combo therapy trial aims to outperform standard for Tough-to-Treat lung cancer brain spread
NCT ID NCT06970639
Summary
This large, international Phase 3 trial is testing if a new drug combination works better than the current standard treatment for a specific type of advanced lung cancer that has spread to the brain. It will compare furmonertinib (a newer targeted drug) given with standard chemotherapy against osimertinib (the current standard targeted drug) given alone. The goal is to see which approach better controls the cancer's growth, especially in the brain, and is safer for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC PATIENTS WITH BRAIN METASTASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial People's Hospital
RECRUITINGGuangdong, Guangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.